pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche
Company profile
Ticker
PIRS
Exchange
Website
CEO
Stephen Yoder
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Marika Inc.
SEC CIK
Corporate docs
Subsidiaries
Pieris Pharmaceuticals GmbH • Pieris Australia Pty Limited • Pieris Pharmaceuticals Securities Corporation ...
PIRS stock data
Latest filings (excl ownership)
8-K
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
18 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
27 Mar 24
8-K
Termination of a Material Definitive Agreement
21 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K/A
Cost Associated with Exit or Disposal Activities
31 Aug 23
S-8
Registration of securities for employees
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
18 Jul 23
8-K
Departure of Directors or Certain Officers
13 Jul 23
Transcripts
PIRS
Earnings call transcript
2023 Q1
10 May 23
PIRS
Earnings call transcript
2022 Q4
29 Mar 23
PIRS
Earnings call transcript
2022 Q3
2 Nov 22
PIRS
Earnings call transcript
2022 Q2
6 Aug 22
PIRS
Earnings call transcript
2022 Q1
11 May 22
PIRS
Earnings call transcript
2021 Q4
1 Mar 22
PIRS
Earnings call transcript
2021 Q3
2 Nov 21
PIRS
Earnings call transcript
2021 Q2
4 Aug 21
PIRS
Earnings call transcript
2021 Q1
17 May 21
PIRS
Earnings call transcript
2020 Q4
30 Mar 21
Latest ownership filings
SC 13G/A
Aquilo Capital Management, LLC
14 Feb 24
SC 13G/A
Checkpoint Capital L.P.
14 Feb 24
SC 13G/A
Lynx1 Capital Management LP
14 Feb 24
SC 13G/A
Soleus Capital Master Fund, L.P.
2 Feb 24
SC 13D/A
BIOTECHNOLOGY VALUE FUND L P
17 Aug 23
4
Ann Barbier
23 Jun 23
4
JAMES A GERAGHTY
23 Jun 23
4
Peter A Kiener
23 Jun 23
4
CHRISTOPHER P KIRITSY
23 Jun 23
4
Michael Richman
23 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 32.89 mm | 32.89 mm | 32.89 mm | 32.89 mm | 32.89 mm | 32.89 mm |
Cash burn (monthly) | 4.01 mm | 1.29 mm | 3.94 mm | 3.06 mm | 3.24 mm | 3.92 mm |
Cash used (since last report) | 26.88 mm | 8.67 mm | 26.35 mm | 20.52 mm | 21.70 mm | 26.27 mm |
Cash remaining | 6.01 mm | 24.23 mm | 6.54 mm | 12.37 mm | 11.19 mm | 6.62 mm |
Runway (months of cash) | 1.5 | 18.7 | 1.7 | 4.0 | 3.5 | 1.7 |
Institutional ownership, Q3 2023
81.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 49 |
Opened positions | 6 |
Closed positions | 12 |
Increased positions | 11 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 11.65 bn |
Total shares | 80.77 mm |
Total puts | 4.30 k |
Total calls | 64.50 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 20.61 mm | $4.66 mm |
BVF | 20.61 mm | $6.14 bn |
Lynx1 Capital Management | 9.78 mm | $2.91 bn |
Checkpoint Capital | 4.94 mm | $4.20 mm |
Soleus Capital Master Fund | 4.00 mm | $6.52 mm |
SGEN Seagen | 3.71 mm | $0.00 |
AZN Astrazeneca | 3.58 mm | $0.00 |
Ran Nussbaum | 3.57 mm | $13.50 mm |
Aquilo Capital Management | 3.30 mm | $984.35 mm |
BLK Blackrock | 1.04 mm | $309.25 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Jun 23 | Sherman Matthew L | Stock Option Common Stock | Grant | Acquire A | No | No | 0.26 | 40,000 | 10.40 k | 40,000 |
21 Jun 23 | Kiritsy Christopher P | Stock Option Common Stock | Grant | Acquire A | No | No | 0.26 | 40,000 | 10.40 k | 40,000 |
21 Jun 23 | Michael Richman | Stock Option Common Stock | Grant | Acquire A | No | No | 0.26 | 40,000 | 10.40 k | 40,000 |
21 Jun 23 | Said Maya R. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.26 | 40,000 | 10.40 k | 40,000 |
21 Jun 23 | Ann Barbier | Stock Option Common Stock | Grant | Acquire A | No | No | 0.26 | 40,000 | 10.40 k | 40,000 |